We are proud to announce a significant milestone for Gulbrandsen Technologies’ Life Sciences business unit—the successful filing of the US Drug Master File (DMF) for Sucralfate API, a trusted anti-ulcer active substance. This achievement underscores our commitment to regulatory excellence and expands our opportunities in the US pharmaceutical market.
A Time-Tested Anti-Ulcer Medication
Sucralfate has been a mainstay in ulcer treatment for decades, effectively managing gastric and duodenal ulcers in humans. Beyond human medicine, veterinarians also rely on Sucralfate to treat ulcers in companion animals and equine species, making it a versatile therapeutic agent.
Dedicated Manufacturing Expertise
At Gulbrandsen Technologies, we have a state-of-the-art dedicated manufacturing block for Sucralfate API, designed to meet global regulatory requirements. Our in-house technology ensures high-quality production, and we also offer micronized powder to meet diverse formulation needs.
Key Advantages of Gulbrandsen’s Sucralfate:
✔ Regulatory-Compliant Manufacturing – Adhering to stringent global standards
✔ Versatile Applications – Suitable for tablets, suspensions, and powder sachets
✔ Micronization Capability – Enhanced formulation performance
This milestone reflects the dedication, collaboration, and expertise of our Regulatory & Life Sciences team, whose relentless efforts made this achievement possible.
Unlocking New Opportunities
With the US DMF filing, Gulbrandsen Technologies is well-positioned to support pharmaceutical partners in bringing high-quality Sucralfate-based products to the market.
Interested in learning more?
Contact us at lifesciences@gulbrandsen.com for detailed information on our Sucralfate API capabilities.
Stay tuned for more updates as we continue to advance innovation and compliance in the pharmaceutical industry!